March 2015 Analysis

Industry Trend Analysis - EU Approval For Ofev In IPF Will Create A Blockbuster In An Intense Market - MAR 2015

EU approval for idiopathic pulmonary fibrosis will act to level the playing field between Ofev and Esbriet, with both now approved in the major markets of Europe and the US. As the first products to be approved for treating this condition in Europe and the US, both products are likely to achieve blockbuster status. However, the relatively small number of patients will mean that competition will...